SMA Newsroom

Last week SMA Europe held its' Annual Meeting and General Assembly. This year, we were hosted by Famiglie SMA in beautiful and sunny Rome.

Today, the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). This means that risdiplam is now approved in the US to treat SMA in children and adults of all ages. 

Listen to interview with Maria. She speaks to us from Ukraine about her reality, her story and her plans for when the war is over. 

The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.